NCT05851105

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 3 (estimated)
• Sponsor: Shenzhen Hemogen · Industry
• Sex: All
• Age: 12 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

Conditions

• α-thalassemia

Interventions

Type	Name	Description
BIOLOGICAL	α-globin restored autologous hematopoietic stem cells	α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C

Timeline

• Start date: 2022-10-08
• Primary completion: 2026-12-30
• Completion: 2026-12-30
• First posted: 2023-05-09
• Last updated: 2024-11-29

Locations

1 site across 1 country: China